User:SerenaCoven/sandbox

6/5/19 - Learning about the wikipedia process. This doesn't seem too difficult. Completed some training and hoping to work on a page for a probiotic bacteria.

6/10/19 - Bartonella henselae

This article is very sparse, lacking in any kind of more detailed information besides the person the bacteria was named after. There are four sources, all of which are good primary or secondary sources. The tone has the proper neutral quality to it. The talk page indicates that the page is part of an effort by Wikipedia to collect more information on the subject of microbiology.

6/14/19 - Bifidobacterium breve

Minami, Junichi et al. “Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: a randomized, double-blind, placebo-controlled trial.” Bioscience of microbiota, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081611/

~B. breve may be linked to chronic obesity. A growing pool of evidence suggests that our natural gut flora can strongly effect how much weight our bodies retain. B.breve is a strong candidate for research concerning this issue.

"BIFIDOBACTERIA.": WEBMD, Therapeutic Research Faculty, 2018, https://www.webmd.com/vitamins/ai/ingredientmono-891/bifidobacteria

~Bifobacteria have been used to treat a number of conditions including constipation, diarrhea, irritable bowel syndrome and even the cold and flue. Some of these uses have been backed up by scientific research but others have not.

Kobayashi, Yodai. "Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease." Nature, 18 October 2017, https://www.nature.com/articles/s41598-017-13368-2

~Bifobacteria and their link to stomach health are being researched along with it's link to the brain through the microbiota–gut–brain axis. Strain A1 of B. Breve has undergone research concerning it's affect on brains suffering from alzheimers. This research has consisted of mouse trails to date and shows promise in reversing or slowing the disease.

6/21/19 - Updated my article with some information and a citation.

6/28/19 - rough draft for final contribution to B. breve article.

Bifidobacterium breve is a bacterial species of the genus Bifidobacterium which has probiotic properties. Bifobacteria have been used to treat a number of conditions including constipation, diarrhea, irritable bowel syndrome and even the cold and flue. Some of these uses have been backed up by scientific research, but others have not.

Clinical Uses
B. breve has been researched and linked to a number of conditions. It may be linked to chronic obesity for example. A growing pool of evidence suggests that our natural gut flora can strongly effect how much weight our bodies retain. B.breve is a strong candidate for research concerning this issue. Bifobacteria and their link to stomach health are being researched along with it's link to the brain through the microbiota–gut–brain axis. Strain A1 of B. Breve has undergone research concerning it's affect on brains suffering from alzheimers. This research has consisted of mouse trails to date and shows promise in reversing or slowing the disease.

History and clinical uses
B. breve strains were originally isolated from the feces of human infants. In 1971, Bifidobacterium parvulorum and Bifidobacterium breve were merged under the name Bifidobacterium breve. Bifidobacterim breve administered in combination with prebiotics or other probiotics and standard therapy has showed some beneficial effect. B. breve is a constituent in the therapeutic, nutritional treatment VSL#3. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and may require a prescription.

Characteristics
B. breve strains can ferment mannitol and sorbitol, but not arabinose or xylose.

7/5/19 - Second draft for B. breve contribution

Bifidobacterium breve is a bacterial species of the genus Bifidobacterium which has probiotic properties. Bifobacteria are a type of bacteria that live symbiotically in the intestines of humans. They have been used to treat a number of conditions including constipation, diarrhea, irritable bowel syndrome and even the cold and flue. Some of these uses have been backed up by scientific research, but others have not.

Clinical Uses
B. breve has been researched and linked to a number of conditions. Bifidobacterim breve administered in combination with prebiotics or other probiotics and standard therapy has showed some beneficial effect. B. breve is a constituent in the therapeutic, nutritional treatment VSL#3. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and may require a prescription. Taking bifobacteria in combination with lactobacillus and normal H. pylori therapy makes the treatment twice as effective while reducing the negative side effects. Bifobacteria can also be used to treat IBS as well, reducing pain, bloating and constipation.

B. breve may be linked to chronic obesity. A growing pool of evidence suggests that our natural gut flora can strongly effect how much weight our bodies retain. B.breve is a strong candidate for research concerning this issue. A study conducted by Bioscience of Microbiota, Food and Heath(BMFH) suggests that treating pre-obese patients with the B-3 strain of B. breve may stop or reverse obesity. However larger studies need to be preformed to confirm these results.

Bifobacteria and their link to stomach health are being researched along with it's link to the brain through the microbiota–gut–brain axis. Strain A1 of B. Breve has undergone research concerning it's affect on brains suffering from alzheimers. This research has consisted of mouse trails to date and shows promise in slowing or reversing the disease.

History
B. breve strains were originally isolated from the feces of human infants. In 1971, Bifidobacterium parvulorum and Bifidobacterium breve were merged under the name Bifidobacterium breve. Bifidobacterim breve administered in combination with prebiotics or other probiotics and standard therapy has showed some beneficial effect. B. breve is a constituent in the therapeutic, nutritional treatment VSL#3. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and may require a prescription.

Characteristics
B. breve strains can ferment mannitol and sorbitol, but not arabinose or xylose.

7/11/19 PEER REVIEW by Kelley Gage How is the grammar (spelling, punctuation, capitalization, appropriate vocabulary)? All of this looks good. Are all species names properly formatted? In the Clinical Uses paragraph, not all of the "B. breve" are italicized. Are there three distinct paragraphs ? Yes. Is each interesting fact elaborated on enough (3-4 sentences at least)? Yes, there is at least 3-4 sentences for each fact. Do any of the paragraphs leave you with further questions? In the clinical uses paragraph you mention the B-3 and A1 strain of B. breve which both seem to do very different things. This makes me wonder how many identified strains there are. ''' I don't believe I can answer this question. People are studying new strains all the time, and by their nature, this bacteria is always forming new strains. As for how many have been researched? That would also be hard for me to say unfortunately as well. That kind of information takes a lot of time to figure out and probably an understanding of multiple languages. '''  Also, the gut-brain axis is mentioned, and I wonder what that is all about. Are the niche and gram stain of the organism mentioned? This article identifies the niche, but I do not see the gram stain. Are 3 sources used throughout the contribution? Yes, there are actually more than three used and cited. Are citations properly formatted? As far as I can tell they are properly formatted. Do the links to citations work when clicked on? Yes, they are working links. Is the contribution written from a neutral tone? Yes, it is written from a neutral tone. Is the contribution written for a lay-audience (someone who might come across this article in the middle of the night on a wiki-binge)? Yes, even if you do not have a background in microbiology, you should be able to understand this article.

7/17/19 - 7/19/19 Bifidobacterium breve is a bacterial species of the genus Bifidobacterium which has probiotic properties. Bifobacteria are a type of bacteria that live symbiotically in the intestines of humans. They have been used to treat a number of conditions including constipation, diarrhea, irritable bowel syndrome and even the cold and flue. Some of these uses have been backed up by scientific research, but others have not. B. breve is a gram positive, aerobic, rod shaped organism that is non motile and forms branches with it's neighbors.

Clinical Uses
B. breve has been researched and linked to a number of conditions. Bifidobacterim breve administered in combination with prebiotics or other probiotics and standard therapy has showed some beneficial effect. B. breve is a constituent in the therapeutic, nutritional treatment VSL#3. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and may require a prescription. Taking Bifobacteria in combination with Lactobacillus and normal Helicobacter pylori therapy makes the treatment twice as effective while reducing the negative side effects. Bifobacteria can also be used to treat IBS as well, reducing pain, bloating and constipation.

B. breve may be linked to chronic obesity. A growing pool of evidence suggests that our natural gut flora can strongly effect how much weight our bodies retain. B.breve is a strong candidate for research concerning this issue. A study conducted by Bioscience of Microbiota, Food and Heath(BMFH) suggests that treating pre-obese patients with the B-3 strain of B. breve may stop or reverse obesity. However larger studies need to be preformed to confirm these results.

Bifobacteria and their link to stomach health are being researched along with it's link to the brain through the microbiota gut–brain axis. Strain A1 of B. Breve has undergone research concerning it's affect on brains suffering from alzheimers. This research has consisted of mouse trials to date and shows promise in slowing or reversing the disease.

History
B. breve strains were originally isolated from the feces of human infants. In 1971, Bifidobacterium parvulorum and Bifidobacterium breve were merged under the name Bifidobacterium breve. Bifidobacterim breve administered in combination with prebiotics or other probiotics and standard therapy has showed some beneficial effect. B. breve is a constituent in the therapeutic, nutritional treatment VSL#3. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and may require a prescription.

Characteristics
B. breve strains can ferment mannitol and sorbitol, but not arabinose or xylose.